Arrowhead Pharmaceuticals, Inc.
ARWR
$82.63
-$2.48-2.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 16.85% | 14.09% | 43,539.24% | 23,258.15% | 2,816.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.85% | 14.09% | 43,539.24% | 23,258.15% | 2,816.21% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 16.85% | 14.09% | 43,539.24% | 23,258.15% | 2,816.21% |
| SG&A Expenses | 47.91% | 41.97% | 34.68% | 21.57% | 9.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.57% | 27.14% | 25.77% | 20.92% | 20.13% |
| Operating Income | -109.74% | -87.17% | 148.02% | 116.36% | 80.27% |
| Income Before Tax | -60.17% | -65.66% | 139.29% | 108.41% | 71.31% |
| Income Tax Expenses | 920.20% | 715.95% | 3,188.91% | 874.09% | 252.56% |
| Earnings from Continuing Operations | -70.77% | -75.76% | 135.96% | 104.94% | 70.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -537.41% | -371.33% | -418.80% | -411.23% | 25.27% |
| Net Income | -115.58% | -109.01% | 131.62% | 99.73% | 72.45% |
| EBIT | -109.74% | -87.17% | 148.02% | 116.36% | 80.27% |
| EBITDA | -134.95% | -101.72% | 153.70% | 120.99% | 83.88% |
| EPS Basic | -80.13% | -57.89% | 130.49% | 99.17% | 73.33% |
| Normalized Basic EPS | -106.67% | -75.58% | 131.19% | 99.55% | 74.56% |
| EPS Diluted | -76.61% | -54.27% | 129.75% | 98.51% | 72.73% |
| Normalized Diluted EPS | -103.16% | -72.92% | 130.60% | 99.08% | 74.05% |
| Average Basic Shares Outstanding | 7.50% | 9.79% | 10.19% | 11.66% | 12.88% |
| Average Diluted Shares Outstanding | 7.97% | 10.27% | 11.16% | 11.89% | 13.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |